TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29463275
Drug: Early parenteral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early parenteral nutrition (PN) initiated within 24 hours of PICU admission
Study: 29463275
Drug: Late parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late parenteral nutrition (PN) withheld for one week in PICU
Study: 29463490
Drug: Motivational interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational interviewing and medication review by a clinical pharmacist, 2 to 5 times over 7 months after standard follow-up at the cardiology clinic.
Study: 29463490
Drug: Motivational interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational interviewing and medication review by a clinical pharmacist.
Study: 29463550
Drug: Glasdegib in
Normalized name: Product containing glasdegib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glasdegib in combination with standard chemotherapy
Study: 29464110
Drug: TAK-228 QD
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-228 QD (3 mg)
Study: 29464110
Drug: TAK-228 3
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-228 3 days/week plus paclitaxel 80 mg/m
Study: 29464110
Drug: TAK-228 QW
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-228 QW (30 mg)
Study: 29464110
Drug: TAK-228 (milled
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-228 (milled capsules)
Study: 29466429
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract capsules standardized to 150 mg epigallocatechin-gallate (EGCG) twice a day for 5 days
Study: 29467098
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral tenofovir diphosphate disoproxil fumarate plus emtricitabine provided at no cost
Study: 29467098
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral tenofovir diphosphate disoproxil fumarate plus emtricitabine
Study: 29467321
Drug: MK-8353 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8353 (400 mg twice daily)
Study: 29467321
Drug: MK-8353 (100-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8353 (100-800 mg dose cohorts)
Study: 29467321
Drug: MK-8353 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8353 (various doses)
Study: 29468069
Drug: Fluid resuscitation
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid resuscitation (≥ 1500 mL)
Study: 29468069
Drug: Adrenergic agents
Normalized name: ANTIADRENERGIC AGENTS, CENTRALLY ACTING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenergic agents
Study: 29468084
Drug: High intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intensity supervision therapy programme over 12 months
Study: 29468084
Drug: Moderate intensity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate intensity supervision therapy programme over 3 months
Study: 29468173
Drug: High Desipramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Desipramine (2-3 mg/kg per day)
Study: 29468173
Drug: Low Desipramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Desipramine (1-2 mg/kg per day)
Study: 29468455
Drug: Crizotinib 250
Normalized name: crizotinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crizotinib 250 mg BID
Study: 29468455
Drug: Crizotinib 200
Normalized name: crizotinib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crizotinib 200 mg BID
Study: 29468455
Drug: Crizotinib not
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Crizotinib not exceeding 250 mg daily
Study: 29470934
Drug: Killed bivalent
Normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Killed bivalent (O1 and O139) whole-cell oral cholera vaccine (OCV), administered in two doses on day 0 and day 14.
Study: 29471876
Drug: Propranolol 40
Normalized name: propranolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 40 mg twice a day for 3 days
Study: 29471930
Drug: Compulsory Center-Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compulsory Center-Based Treatment (CCT)
Study: 29472362
Drug: Tadekinig alfa
Normalized name: Tadekinig alfa
DrugBank: Tadekinig alfa (DB14858)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadekinig alfa 80 mg
Study: 29472362
Drug: Tadekinig alfa
Normalized name: Tadekinig alfa
DrugBank: Tadekinig alfa (DB14858)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadekinig alfa 160 mg
Study: 29472362
Drug: Tadekinig alfa
Normalized name: Tadekinig alfa
DrugBank: Tadekinig alfa (DB14858)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadekinig alfa (both doses)
Study: 29474102
Drug: Early palliative
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early palliative care visits addressing treatment decisions
Study: 29474286
Drug: Cranberry capsules
DrugBank: Cranberry (DB10631)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry capsules (implemented in April to September 2016)
Study: 29474286
Drug: No cranberry
Approvals — FDA: no, EMA: no, PMDA: no
Description: No cranberry capsules (April to September 2015)
Study: 29474293
Drug: Pain medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain medication use prior to surgery
Study: 29474336
Drug: Total endocan
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total endocan levels higher than 4.46 ng/mL
Study: 29474345
Drug: Morphine titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine titrated in the postanaesthesia care unit (PACU) and patient-controlled intravenous analgesia for 24 hours.
Study: 29474345
Drug: Morphine-related adverse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine-related adverse events observed in patients.
Study: 29474450
Drug: Native heterodimeric
Normalized name: Castanea sative leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Native heterodimeric IL-15 (hetIL-15) treatment
Study: 29474565
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy recommendation
Study: 29475723
Drug: Umbralisib (TGR-1202)
Normalized name: Umbralisib
DrugBank: Umbralisib (DB14989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Umbralisib (TGR-1202) administered orally once per day in 28-day cycles, starting dose of 50 mg, escalating to 1200 mg, with 800 mg of micronised formulation selected as the recommended phase 2 dose.
Study: 29475762
Drug: rBV A/B
Normalized name: rBV A/B
DrugBank: Recombinant botulinum A/B vaccine (DB17830)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rBV A/B vaccine (0.5 mL, 40-microgram intramuscular injection)
Study: 29476383
Drug: Linsitinib 150
Normalized name: Linsitinib
DrugBank: Linsitinib (DB06075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linsitinib 150 mg orally twice daily on a 28-day cycle
Study: 29476660
Drug: Micra leadless
Normalized name: Lipantil Micro
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micra leadless pacemaker implantation and concurrent AVJ ablation
Study: 29477307
Drug: trivalent oral
Normalized name: poliovirus vaccine, live, trivalent oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: trivalent oral poliovirus vaccine (tOPV)
Study: 29477307
Drug: tOPV together
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tOPV together with a dose of inactivated poliovirus vaccine (IPV)
Study: 29477412
Drug: Dextromethorphan 20
Normalized name: dextromethorphan 20 mg/15 mL oral syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan 20 mg / Quinidine 10 mg (DM/Q) twice daily for 90 days
Study: 29477578
Drug: Daily physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily physical activity (DPA) and energy expenditure (EE) assessed over 48 hours using a wearable armband system
Study: 29477578
Drug: Insulin sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin sensitivity (IS) measured by euglycaemic insulin clamp
Study: 29477778
Drug: Carlecortemcel-L (expanded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carlecortemcel-L (expanded cord blood units with cytokines and tetraethylenepentamine)
Study: 29478026
Drug: Atenolol (β1-adrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (β1-adrenergic receptor blocker) - monotherapy
Study: 29478026
Drug: Atenolol (β1-adrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (β1-adrenergic receptor blocker) - add-on therapy
Study: 29478343
Drug: Avelumab (human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avelumab (human IgG1 monoclonal antibody against PD-L1)
Study: 29478347
Drug: One-dose MMR
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-dose MMR
Study: 29480357
Drug: Etanercept (ETN)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept (ETN) 50 mg/week for 24 weeks followed by ETN for 28 weeks
Study: 29480357
Drug: Placebo (PBO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PBO) for 28 weeks after initial treatment with ETN
Study: 29481737
Drug: Subcutaneous abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous abatacept (weight-tiered: 50 mg for 10 to <25 kg, 87.5 mg for 25 to <50 kg, 125 mg for ≥50 kg) administered weekly for 24 months.
Study: 29481926
Drug: 5,000 units
Normalized name: Lapase, 1200 units-15,000 units-15,000 units oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5,000 units of unfractionated heparin (UFH)
Study: 29481970
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of vedolizumab and adalimumab
Study: 29481970
Drug: Current therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current therapies (biologic agents)
Study: 29483892
Drug: Baseline mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline mean monthly number of attacks
Study: 29483892
Drug: End of
Normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: End of 3-month diet mean monthly number of attacks
Study: 29483909
Drug: Autoantibodies (AAb)
Normalized name: insulin lispro-aabc Cartridge [Lyumjev]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autoantibodies (AAb) against G protein-coupled receptors (GPCRs) in patients with POAG and OHT.
Study: 29484172
Drug: Apnoeic oxygenation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apnoeic oxygenation (3 l/min oxygen by nasal cannula)
Study: 29484198
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (PT) program consisting of exercises designed to improve balance and gait, conducted over 8 weeks, twice weekly.
Study: 29484198
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving the current standard of care following STN-DBS, which does not include prescription of PT.
Study: 29484198
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (PT) program
Study: 29484495
Drug: Levodopa alone
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa alone or in combination with a dopamine agonist
Study: 29484495
Drug: Dopaminergic monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopaminergic monotherapy
Study: 29484495
Drug: Dopamine-substituting therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine-substituting therapies
Study: 29485066
Drug: Hypofractionated adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated adjuvant whole breast/chest wall and/or regional nodal radiation therapy, 34 Gy in 10 fractions within 2 weeks, followed by a boost of 10 Gy in 5 fractions within 1 week for BCS patients.
Study: 29485066
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment of 35 Gy in 15 fractions within 3 weeks (not explicitly detailed in the abstract).
Study: 29486723
Drug: Pembrolizumab (PD-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (PD-1 immunotherapy)
Study: 29486723
Drug: Chemokine and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemokine and immunosuppressive molecule expression profiles
Study: 29486869
Drug: CORT (cortisol
Approvals — FDA: no, EMA: no, PMDA: no
Description: CORT (cortisol administration)
Study: 29486918
Drug: Selective internal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective internal radiation therapy (SIRT)
Study: 29486918
Drug: Selective internal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective internal radiation therapy (SIRT) followed by surgery
Study: 29487070
Drug: Anti-CD22 moxetumomab
Normalized name: Allogenic engineered T cells expressing anti-CD22 CAR UCART22
DrugBank: UCART22 (DB17466)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-CD22 moxetumomab pasudotox (50 µg/kg every other day for 3 doses in 4-week cycles)
Study: 29487070
Drug: Anti-CD22 moxetumomab
Normalized name: Allogenic engineered T cells expressing anti-CD22 CAR UCART22
DrugBank: UCART22 (DB17466)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-CD22 moxetumomab pasudotox (50 µg/kg)
Study: 29487219
Drug: Selinexor (65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor (65 mg/m, twice-a-week dosing)
Study: 29487221
Drug: Ablation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ablation therapy after six cycles of chemotherapy
Study: 29487556
Drug: Long-term pain
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term pain treatment
Study: 29487697
Drug: 5-fluorouracil- and
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil- and irinotecan-based chemotherapy regimens (FOLFIRI or FOLFOXIRI) plus bevacizumab
Study: 29487870
Drug: Radon water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radon water therapy
Study: 29487870
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no radon water therapy)
Study: 29488303
Drug: Glasdegib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glasdegib (100 mg) alone
Study: 29488303
Drug: Glasdegib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glasdegib (100 mg) following rifampin (600 mg) pre-treatment
Study: 29489073
Drug: Atomoxetine (pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (pharmacotherapy for cannabis dependence)
Study: 29489559
Drug: Structured breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured breast implants
Study: 29490682
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of Tranexamic Acid (TXA)
Study: 29490682
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g of Tranexamic Acid (TXA)
Study: 29490680
Drug: BESMILE-HF program
Approvals — FDA: no, EMA: no, PMDA: no
Description: BESMILE-HF program plus usual medications
Study: 29490690
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TA) 0.5 g
Study: 29490690
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TA) 1 g
Study: 29490690
Drug: TA (0-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: TA (0-2 g) in H patients
Study: 29490924
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of antiphospholipid antibodies (APAs)
Study: 29491412
Drug: BI 894999
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 894999 (novel BET bromodomain inhibitor)
Study: 29491412
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of BI 894999 and CDK9 inhibitors
Study: 29497534
Drug: Intravenous IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous IgM immunoglobulin therapy (IVIG group)
Study: 29497535
Drug: High-dose norepinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose norepinephrine (≥ 416 μg/kg/week)
Study: 29497535
Drug: Low-dose norepinephrine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose norepinephrine (not specified)
Study: 29498038
Drug: Dupilumab (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab (subcutaneous 300 mg weekly)
Study: 29498742
Drug: ATV/r monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATV/r monotherapy (300/100 mg)
Study: 29498742
Drug: ATV/r triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATV/r triple therapy (300/100 mg + 2 NRTIs)
Study: 29498742
Drug: Both ATV/r
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both ATV/r monotherapy and ATV/r triple therapy
Study: 29498742
Drug: ATV/r monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATV/r monotherapy
Study: 29499622
Drug: Stress ulcer
Normalized name: adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Stress ulcer prophylaxis (SUP) using acid-suppression drugs
Study: 29499622
Drug: SUP (acid-suppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUP (acid-suppression drugs)
Study: 29499622
Drug: Hemostatic drugs
Normalized name: collagen hemostat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemostatic drugs
Study: 29499662
Drug: Sorafenib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib at 800 mg/day
Study: 29499740
Drug: Low-dose transdermal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose transdermal hydrogel MSCs (3 × 10)
Study: 29499753
Drug: OMPSQ-G (Orebro
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMPSQ-G (Orebro musculoskeletal pain screening questionnaire - German version)
Study: 29499753
Drug: OMPSQ-G
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMPSQ-G
Study: 29500160
Drug: Testosterone injections
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone injections and therapist-assisted progressive resistance training for 20 weeks
Study: 29500160
Drug: Testosterone injections
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone injections for 20 weeks without physical exercise
Study: 29500160
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections for 20 weeks combined with 16 weeks of progressive strength training
Study: 29500160
Drug: Testosterone injections
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone injections for 20 weeks combined with 16 weeks of progressive strength training
Study: 29500160
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections without physical exercise for 20 weeks
Study: 29500162
Drug: Community Health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community Health Extension Workers (CHEWs) providing contraceptive subdermal implants
Study: 29500162
Drug: Nurses and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurses and midwives providing contraceptive subdermal implants
Study: 29500572
Drug: Ciprofloxacin (CIP)
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin (CIP) 750 mg prophylaxis
Study: 29500837
Drug: Soft tissue
Normalized name: INSULIN DETEMIR 14.2 mg in 1 mL SOFT TISSUE IMPLANT [Levemir]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft tissue grafting or implant surgery
Study: 29500837
Drug: Pain pill
Normalized name: papain Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain pill use
Study: 29501599
Drug: Deep healing
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep healing (combination of transmural and mucosal healing)
Study: 29502304
Drug: Insulin dosing
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin dosing errors (lay-users)
Study: 29502304
Drug: Insulin dosing
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin dosing errors (study personnel)
Study: 29504483
Drug: sTMS (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: sTMS (four pulses twice daily)
Study: 29506523
Drug: RAAS inhibition
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAAS inhibition treatment
Study: 29506984
Drug: LDL-C <100
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C <100 mg/dL
Study: 29506988
Drug: Cetuximab in
Normalized name: cetuximab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab in combination with FOLFIRI
Study: 29507070
Drug: Intravenous ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ganciclovir therapy; specific dosage and duration not mentioned.
Study: 29507077
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin with cyclophosphamide, doxorubicin, and prednisone (BV+CHP; 6 cycles, then up to 10 cycles of brentuximab vedotin monotherapy)
Study: 29507099
Drug: 24-hour urinary
Normalized name: Urinary hCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour urinary sodium excretion (118.7 mmol)
Study: 29507732
Drug: Occupational multicomponent
Normalized name: meningococcus B, multicomponent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational multicomponent rehabilitation including physical exercise and cognitive behavioral therapy (ACT) for either 8 or 17 full days.
Study: 29507971
Drug: Grazoprevir (GZR),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grazoprevir (GZR), 100 mg, and Elbasvir (EBR), 50 mg, immediately before transplantation; continued GZR-EBR for 12 weeks after transplantation for genotype 1 infection, and added Sofosbuvir, 400 mg, for genotype 2 or 3 infection for 12 weeks of triple therapy.